Can I Take Green Tea Extract (EGCG) With NMN or NR?

What the Interaction Actually Is

The short answer: this is not a classic drug-drug interaction with a clean pharmacokinetic mechanism. Instead, NMN, NR, and green tea extract (EGCG) overlap in two ways that matter clinically. First, green tea extract is metabolized partly through CYP-mediated liver pathways, and EGCG can inhibit certain CYP enzymes, which may change how your body processes other compounds taken at the same time. Second, both green tea extract at high doses and, theoretically, high NAD+ flux can place oxidative or metabolic demands on the liver that compound rather than simply add together.

Neither NMN nor NR has a well-characterized CYP interaction profile in published human pharmacokinetic studies. A 2023 pharmacokinetic study in healthy adults confirmed that NMN is absorbed and converted to NAD+ in blood, but it did not measure CYP enzyme effects. That is an evidence gap worth naming plainly: we do not yet have human data on whether NMN or NR meaningfully alter the metabolism of co-ingested compounds.

The Green Tea Extract Hepatotoxicity Signal

This is the part most supplement articles skip. Green tea extract, specifically concentrated EGCG, is one of the most commonly implicated herbal supplements in drug-induced liver injury (DILI). The U.S. Drug-Induced Liver Injury Network has catalogued multiple cases, and the European Food Safety Authority (EFSA) concluded in its 2018 scientific opinion that doses of EGCG at or above 800 mg/day raise safety concerns, while doses below 338 mg/day are considered safe for most adults. Cases have been reported with widely available commercial products, and several involved women taking green tea extract for weight management.

The mechanism appears to involve reactive oxygen species generated during EGCG catabolism overwhelming hepatic antioxidant defenses, rather than a classic CYP inhibition event. Taking green tea extract in a fasted state significantly increases peak EGCG plasma concentrations and is associated with a higher risk of GI and liver adverse effects compared with taking it with food.

Where NMN and NR Enter the Picture

NMN and NR are both NAD+ precursors. After absorption, NMN is converted to NMN inside cells and then to NAD+; NR follows a slightly different route through NMN as an intermediate, depending on the tissue. A 2022 randomized trial (Yoshino et al., Cell Metabolism) showed NMN supplementation at 250 mg/day for 10 weeks increased skeletal muscle NAD+ metabolite levels in postmenopausal women with prediabetes, without significant liver enzyme changes.

At physiological doses, NMN and NR do not appear to be hepatotoxic. The concern when combining them with high-dose green tea extract is additive metabolic load rather than a specific enzyme interaction. Think of it as two separate stressors on the same organ, not one drug blocking the clearance of another.

How EGCG Affects Liver Enzymes and CYP Pathways

CYP1A2 and CYP3A4 Inhibition

EGCG inhibits CYP1A2 and, to a lesser degree, CYP3A4 in in-vitro and some in-vivo studies. CYP1A2 metabolizes caffeine, some antidepressants (fluvoxamine, duloxetine), and estradiol. If you take high-dose green tea extract alongside these medications, plasma levels of the co-administered compound could rise. For NMN and NR specifically, CYP1A2 inhibition is not thought to matter much because NAD+ precursors are not primarily CYP substrates. The clinical significance of EGCG's CYP inhibition for NMN or NR metabolism is therefore low.

Why Fasting State Changes Everything

EGCG bioavailability increases approximately 3.5-fold when taken fasted versus fed. Many people take NMN first thing in the morning on an empty stomach because some animal data suggest morning NAD+ supplementation aligns with circadian NAD+ rhythms. If you also take fasted green tea extract, you are getting peak EGCG exposure at the same time. Taking green tea extract with food, or separating it from NMN by at least 30 to 60 minutes with a small meal, reduces peak EGCG load and is a practical harm-reduction step.

COMT Inhibition and Estrogen Metabolism

EGCG inhibits catechol-O-methyltransferase (COMT), an enzyme involved in estrogen metabolism and the breakdown of catecholamine neurotransmitters. In vitro data suggest EGCG can slow the methylation of catechol estrogens, which are metabolites of estradiol. The clinical relevance in women is uncertain, but it is a reason to be thoughtful about high-dose green tea extract use in women with estrogen-sensitive conditions such as ER-positive breast cancer history or endometriosis. NMN and NR do not have a known direct effect on COMT.

Sex-Specific Physiology: What Changes for Women

Reproductive Years

Women in their 20s and 30s taking NMN or NR for energy, cycle-related fatigue, or skin health typically use standard doses (250 to 500 mg/day). At these doses, the interaction risk with green tea extract at typical supplement doses (200 to 400 mg EGCG/day) is low. Cycle phase may subtly alter NAD+ metabolism: a 2021 review in Aging Cell noted that estrogen signaling influences NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway, which means NAD+ synthesis is not hormonally neutral.

If you have PCOS, note that metformin (sometimes prescribed for PCOS) is also cleared partly through renal transporters that overlap with NR absorption pathways, and EGCG may modestly inhibit organic cation transporter function in vitro. Human data on this triple interaction are absent; consider discussing with your prescriber.

Perimenopause and Menopause

This is where the NMN and NR conversation is most active clinically. NAD+ levels decline with age, and the rate of decline in women appears to accelerate around the menopause transition. A 2023 review in Menopause summarized preclinical evidence that NAD+ replenishment may support mitochondrial function in aging ovarian tissue, though no large RCT in perimenopausal women has confirmed clinical benefit yet. That is an important evidence gap.

For perimenopausal women, consider this decision framework when evaluating NMN/NR plus green tea extract:

Tier 1 (lowest risk): Dietary green tea (2 to 3 cups/day, approximately 100 to 150 mg EGCG total) with NMN or NR at 250 to 500 mg/day. No dose separation required. No liver monitoring required in healthy women with normal baseline LFTs.

Tier 2 (monitor): Supplement-grade green tea extract at 300 to 500 mg EGCG/day with NMN or NR. Take green tea extract with food, not fasted. Consider checking a hepatic panel at baseline and at 3 months if using this combination long-term.

Tier 3 (discuss with clinician): Green tea extract above 500 mg EGCG/day combined with NMN/NR, especially if you are also taking hormone therapy, antidepressants, statins, or thyroid medications. Liver monitoring is reasonable. Duration should be purposeful, not indefinite.

Women on hormone therapy should be aware that EGCG's COMT inhibition could theoretically alter the metabolism of catechol estrogens derived from exogenous estradiol, though the clinical significance has not been quantified in HT users specifically.

Postmenopause

Postmenopausal women have lower baseline estrogen, which removes some of the COMT-estrogen concern. NAD+ decline is well-established in this group. The Yoshino 2022 Cell Metabolism trial specifically enrolled postmenopausal women with prediabetes and found 250 mg/day NMN improved muscle insulin sensitivity compared to placebo over 10 weeks, though it did not improve whole-body glucose tolerance. No green tea extract was co-administered in this trial. Bone health, metabolic function, and cardiovascular risk are all relevant comorbidities in this group, and some women use green tea extract for lipid or blood pressure support alongside NAD+ precursors. Standard-dose combinations appear to be well-tolerated based on available case reports, but prospective safety data are lacking.

Pregnancy, Lactation, and Contraception

Do not take high-dose green tea extract during pregnancy. This is not equivocal. EGCG at high doses is a folate antagonist: it inhibits dihydrofolate reductase (DHFR), the enzyme that activates folic acid. A 2011 study in the American Journal of Clinical Nutrition demonstrated that high EGCG intake impairs folate bioavailability, which is a direct fetal neural tube defect risk. The FDA has not assigned a formal pregnancy category to EGCG as a supplement, but ACOG advises caution with high-dose herbal supplements in pregnancy and recommends limiting caffeine to under 200 mg/day, noting that green tea products contribute variable caffeine.

NMN and NR have no adequate human safety data in pregnancy. Animal data show NAD+ precursors are necessary for normal embryonic development, but supplementation beyond dietary sources has not been tested in pregnant women. The precautionary position is to avoid both NMN and NR supplementation during pregnancy and to use reliable contraception if you are taking other compounds with teratogenic potential in your regimen.

During lactation, EGCG does transfer into breast milk. A 2018 pharmacokinetic study detected EGCG in breast milk after green tea consumption, though at lower concentrations than maternal plasma. NMN and NR transfer into breast milk is unstudied. Given the absence of safety data, both green tea extract supplements and NMN/NR supplementation beyond dietary tea intake are best avoided while breastfeeding.

If you are trying to conceive, dietary green tea (2 to 3 cups/day) is generally acceptable. Concentrated green tea extract capsules should be stopped before an anticipated conception given the folate antagonism concern.

Female-Relevant Conditions: Special Considerations

PCOS

Women with PCOS often experience mitochondrial dysfunction and insulin resistance, which is the same metabolic terrain NMN and NR are theorized to improve. A 2022 meta-analysis in Frontiers in Endocrinology found green tea extract modestly improved insulin sensitivity and reduced fasting insulin in women with PCOS. There is theoretical complementarity between green tea extract and NAD+ precursors in PCOS, but no trial has tested the combination. Liver enzyme monitoring is a reasonable addition for PCOS patients combining both, particularly those who are also on metformin or inositol.

Thyroid Conditions

EGCG can modestly inhibit thyroid peroxidase (TPO) in in vitro models, raising a theoretical concern for women with Hashimoto's thyroiditis or those on levothyroxine. A 2017 review in Thyroid Research noted this effect appears dose-dependent. At typical dietary intake levels, this is unlikely to be clinically significant. At high supplement doses, TSH monitoring in women with thyroid conditions is a reasonable precaution.

Estrogen-Sensitive Conditions

Women with a personal history of ER-positive breast cancer, endometriosis, or fibroids should discuss high-dose green tea extract with their oncologist or OB-GYN before using it alongside NMN or NR. EGCG has been studied as an anti-estrogenic agent in some cancer models and as a pro-estrogenic compound in others, and the net clinical effect in human tissue is not settled.

Who This Combination Is Right For (and Who Should Be Cautious)

Generally Acceptable

You are a reasonable candidate for combining dietary green tea or low-dose green tea extract with NMN or NR if you:

• Are a healthy adult woman in your reproductive years or postmenopause with no liver disease
• Use supplement-grade green tea extract at or below 300 mg EGCG/day, taken with food
• Have no history of liver disease, alcohol use disorder, or concurrent hepatotoxic medications
• Are not pregnant, not breastfeeding, and not actively trying to conceive

Use Extra Caution or Get Clinical Input First

Consider a conversation with your clinician before combining these supplements if you:

• Take hormone therapy (estradiol patch, pill, or gel), since COMT inhibition may alter estrogen metabolite profiles
• Use antidepressants metabolized by CYP1A2, such as fluvoxamine or duloxetine
• Have diagnosed liver disease, elevated baseline ALT or AST, or a history of DILI
• Have PCOS and are on metformin
• Have thyroid disease and are on levothyroxine
• Are trying to conceive, pregnant, or breastfeeding (avoid concentrated green tea extract entirely)
• Plan to use green tea extract above 500 mg EGCG/day for any reason

Practical Dosing and Timing Guidance

You do not need to take these supplements at different times of day to avoid a direct pharmacokinetic clash in most cases. The practical rules are:

1. Take green tea extract with food, never fasted. This is the single most effective step to reduce peak EGCG exposure and GI side effects.
2. Choose a standardized product. Look for supplements that state the EGCG content (not just "green tea extract") and have been third-party tested. Mislabeled products are a genuine source of unexpected high-dose exposure.
3. Start low. If you are new to green tea extract, start at 200 mg EGCG/day for 4 weeks before increasing, regardless of whether you are also taking NMN or NR.
4. Know the warning signs. Jaundice, dark urine, upper-right abdominal discomfort, or unexplained fatigue in the first 3 months of use warrant stopping green tea extract and checking liver enzymes promptly.
5. Duration matters. There is no evidence base for continuous, indefinite use of high-dose green tea extract. Cycling off (for example, 8 to 12 weeks on, 4 weeks off) is a reasonable approach until better safety data exist, though this is expert opinion rather than guideline-based practice.

What the Evidence Still Does Not Tell Us

Be clear-eyed about the limits here. No randomized trial has studied NMN plus green tea extract co-administration in women or men. The hepatotoxicity risk for the combination is inferred from green tea extract's solo safety profile, not from direct evidence. NMN and NR's CYP interaction profiles have not been characterized in human pharmacokinetic studies. The specific effects of this combination across the menstrual cycle, during perimenopause, or on HT pharmacokinetics are unstudied.

Women have been historically underrepresented in supplement safety trials. A 2020 analysis in JAMA Network Open found that women comprise fewer than 40% of participants in most longevity-focused supplementation trials, meaning much of what we think we know is extrapolated from male-dominant datasets. The Yoshino 2022 NMN trial is a notable exception because it enrolled only postmenopausal women, making it one of the most directly relevant human datasets available.

The honest clinical position: at standard doses, taken with food, this is a low-risk combination for most healthy women. At high green tea extract doses, the risk is real and the benefit-to-risk math shifts unfavorably, especially given the absence of strong human evidence that green tea extract supplements (as opposed to dietary green tea) produce meaningful longevity or metabolic benefits.

If your baseline liver enzymes are normal and you use EGCG at or below 300 mg/day with food alongside NMN at 250 to 500 mg/day or NR at 250 to 500 mg/day, checking a hepatic panel at 3 months is a reasonable, low-cost safety net.